https://alzheimereurope.newsweaver.com/Newsletter/ en-us 05 May 2025 05:20:09 CEST 05 May 2025 05:20:09 CEST https://alzheimereurope.newsweaver.com/Newsletter/rss.xml Newsweaver info@alzheimer-europe.org () support@newsweaver.ie (Newsweaver) 60 true https://alzheimereurope.newsweaver.com/Newsletter/9vhc7n86pfo?lang=en?rss=true Alzheimer Europe's April 2025 newsletter [ https://alzheimereurope.newsweaver.com/Newsletter/10sdaddpmxq/external ] [ https://alzheimereurope.newsweaver.com/Newsletter/10sdaddpmxq/external ] brings you the latest news on developments in the dementia field, across Europe and beyond. Summaries of a few of our top stories appear below. Our monthly newsletter reaches almost 11,000 people, who have an interest in dementia, from across Europe and beyond. We are always happy to receive feedback, or suggestions regarding news items to share. [ https://alzheimereurope.newsweaver.com/Newsletter/10sdaddpmxq/external ] 05 May 2025 12:00:00 CEST 3c81ce735ac8ccd6b5ee9a5d7d6c6045 Feature Article <p style="text-align: justify;"><span style="font-size: 12px;"><img align="left" src="https://alzheimereurope.newsweaver.com/v3files/shard1/56305/19/ea8a85fca407401059a769.jpg" style="margin: 5px;" width="133" height="200" hspace="5" vspace="5" alt="Executive Director Jean Georges, June 2024">Alzheimer Europe's <strong><span style="color: #004b96;"><a href="https://alzheimereurope.newsweaver.com/Newsletter/10sdaddpmxq/external" target="_blank" rel="noreferrer noopener"><strong>April 2025 newsletter</strong></a> </span></strong>brings you the latest news on developments in the dementia field, across Europe and beyond.</span></p> <p style="text-align: justify;"><span style="font-size: 12px;">Summaries of a few of our top stories appear below.</span></p> <p style="text-align: justify;"><span style="font-size: 12px;">Our monthly newsletter reaches almost 11,000 people, who have an interest in dementia, from across Europe and beyond.</span></p> <p style="text-align: justify;"><span style="font-size: 12px;">We are always happy to receive feedback, or suggestions regarding news items to share.</span></p> <p style="text-align: justify;"> </p> <p class="centered-only" style="text-align: center;"><a href="https://alzheimereurope.newsweaver.com/Newsletter/10sdaddpmxq/external" target="_blank" rel="noreferrer noopener"><img align="middle" src="https://alzheimereurope.newsweaver.com/v3files/shard1/56305/33/9a2b2c753c2ca4ee114ecc.jpg" style="margin: 0px;" width="200" height="48" hspace="0" vspace="0" alt=""></a></p> https://alzheimereurope.newsweaver.com/Newsletter/1t6o9bziw45?lang=en?rss=true A warm welcome to two new arrivals who joined the Alzheimer Europe team in April: Isabelle Collot, who is our new Conference Coordinator and Margarita Reyes, who joins the team as a Communications Officer. We are all delighted to be working with them both! 05 May 2025 12:00:00 CEST 4a790838d102455a47bc186c68e02343 Other Articles <p style="text-align: justify;"><img align="left" src="https://alzheimereurope.newsweaver.com/v3files/shard1/56305/91/9d1ea346adc18688eaf2c9.jpg" style="margin: 5px;" width="150" height="150" hspace="5" vspace="5" alt="">A warm welcome to two new arrivals who joined the Alzheimer Europe team in April: Isabelle Collot, who is our new Conference Coordinator and Margarita Reyes, who joins the team as a Communications Officer. We are all delighted to be working with them both!</p> https://www.alzheimer-europe.org/news/alzheimer-europe-welcomes-two-new-colleagues-1 https://alzheimereurope.newsweaver.com/Newsletter/1kd660uofju?lang=en?rss=true The European Commission has granted EU authorisation for lecanemab to treat mild cognitive impairment (MCI) in the early stages of Alzheimer’s disease. This authorisation comes under strict conditions, with the drug being for use in people who have only one or no copy of the ApoE4 gene and who have amyloid beta plaques in the brain. 05 May 2025 12:00:00 CEST 01de8fd582079b04ae5e48c0fbf1e74e Other Articles <p style="text-align: justify;"><img align="left" src="https://alzheimereurope.newsweaver.com/v3files/shard1/56305/a3/255c41ff48efa2fe858667.jpg" style="margin: 5px;" width="150" height="145" hspace="5" vspace="5" alt="EU Commission building and EU flags">The European Commission has granted EU authorisation for lecanemab to treat mild cognitive impairment (MCI) in the early stages of Alzheimer’s disease. This authorisation comes under strict conditions, with the drug being for use in people who have only one or no copy of the ApoE4 gene and who have amyloid beta plaques in the brain. </p> https://www.alzheimer-europe.org/news/alzheimer-europe-welcomes-news-european-commission-has-authorised-lecanemab-treatment-early?language_content_entity=en https://alzheimereurope.newsweaver.com/Newsletter/11yx6rlaww8?lang=en?rss=true Alzheimer Europe, Alzheimer Uniti Italia and Federazione Alzheimer Italia would like to thank everyone who submitted abstracts for the 35th Alzheimer Europe Conference (#35AEC), taking place from 6-8 October 2025, in Bologna (Italy). A record number of 926 abstracts was received this year, which will be reviewed by our Scientific Committee during May. 05 May 2025 12:00:00 CEST cc1bc41760e7a3314a5219d30365c5b9 Other Articles <p style="text-align: justify;"><img align="left" src="https://alzheimereurope.newsweaver.com/v3files/shard1/56305/be/b05ffb8420ecd2e0f623dc.jpg" style="margin: 5px;" width="150" height="150" hspace="5" vspace="5" alt="35AEC Bologna teaser image square">Alzheimer Europe, Alzheimer Uniti Italia and Federazione Alzheimer Italia would like to thank everyone who submitted abstracts for the 35th Alzheimer Europe Conference (#35AEC), taking place from 6-8 October 2025, in Bologna (Italy). A record number of 926 abstracts was received this year, which will be reviewed by our Scientific Committee during May.</p> https://www.alzheimer-europe.org/news/record-number-abstracts-submitted-years-alzheimer-europe-conference?language_content_entity=en